Following the December 2011, ruling by the Federal Drug and Administration (FDA) that the label warnings on Yaz and Yasmin failed to adequately warn against the increased risk of blood clots, Bayer began contacting Plaintiffs across the country to settle their Yaz lawsuit. In April 2012, a Bloomberg article reported that Bayer had already settled more than 600 cases involving women who had suffered a heart attack, Yaz stroke, deep vein thrombosis or pulmonary embolism for a combined total of $142 million dollars. The breakdown of the average recovery is difficult to predict as the cases are individually evaluated based on the specific injury. Unfortunately, at this time, Bayer is not negotiating the settlement of women who allegedly developed Yaz gallbladder disease as a result of taking the drug, but Plaintiffs’ counsel are still hopeful of their ultimate resolution.
According to a recent Bloomberg article, Yaz remains the fourth best-selling oral contraceptive on the market, earning Bayer $1.5 billion in 2010. It is projected that Bayer may ultimately pay over $2 billion dollars to settle the pending lawsuits, which at one time totaled more than 11,000 cases. Bayer’s counsel is continuing to schedule meetings with law firms nationwide to discuss settlement.
If you have suffered a Yaz stroke, heart attack, deep vein thrombosis or pulmonary embolism while taking YAZ® or Yasmin®, contact Stark & Stark and speak to one of the Mass Tort/Pharmaceutical Litigation attorneys, free of charge, to help you assess any claims that you might have against the YAZ® or Yasmin® manufacturers.